Corporate Information – Page 3

iZafe Group receives confirmed order for 1,000 Dosell units to the Netherlands

iZafe Group AB ("iZafe Group") announces today that they have received an official order for 1,000 units of Dosell in accordance with the agreement announced on February 27, 2023. These units will be produced as soon as possible and are expected to be delivered to IVE Ventures ("IVE") in February 2024.

Earlier this year, iZafe announced an exclusive partnership with IVE, giving them the sole rights to sell and market Dosell medication robots in the Netherlands. According to this agreement, IVE committed to purchasing a minimum of 1,000 Dosell units each year for a three-year period to retain exclusivity. The total value of hardware purchases and license revenues over the first three years amounts to approximately 16 million SEK, with annual recurring license revenues of at least 6 million SEK thereafter.

"We look forward to continuing our partnership with iZafe Group and introducing Dosell to the Dutch market. This order for 1,000 units is a clear demonstration of our dedication to promoting innovative health and healthcare solutions," says Martijn Van Bree, CEO of IVE Ventures.

IVE's commitment to improving health and healthcare solutions and their dedication to Dosell is evident through their initial order of 1,000 Dosell units. Their promise to annually purchase at least 1,000 units to maintain exclusivity in the Dutch market reflects their strategic approach to strengthening their portfolio. With extensive experience in providing connected health and healthcare services since 2014, IVE has identified Dosell's potential to enhance and provide a reliable and secure medication solution to their customers in healthcare and alarm services in the Netherlands.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group receives confirmed order for 1,000 Dosell units to the Netherlands

Självständig Medicinering Hemtjänst

Helsingborg Municipality cancels procurement – iZafe Group ready for a new opportunity in January

iZafe Group AB ('iZafe Group') announces that the award decision, which was announced on December 8, 2023, where iZafe Group won the procurement with Helsingborg Municipality for the delivery of Dosell medication dispensers, has now led to the city choosing to cancel the process. This decision is motivated by identified shortcomings in the municipality's procurement documents.

The previous press release was published on December 8, 2023, announcing that iZafe Group had won the procurement with a potential value ranging from 5.5 to 13.8 million SEK for 150–400 Dosell medication dispensers. The award decision was not legally binding.
Despite the interruption, iZafe Group remains optimistic and looks forward to showcasing its expertise once the procurement is resumed.

"It is regrettable that the procurement has been interrupted, but we see this as an opportunity to improve and continue our positive dialogue with Helsingborg Municipality. We are ready to participate again when the procurement is expected to resume in January 2024," says Anders Segerström, CEO of iZafe Group.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Helsingborg Municipality cancels procurement – iZafe Group ready for a new opportunity in January

100512242 Dosell Lkemedelsautomat

iZafe group has won procurement for pharmaceutical robots potentially worth SEK 5.5-13.8 million

iZafe Group AB ("iZafe Group") announces that it has been awarded a contract in a procurement with the Municipality of Helsingborg for the provision of iZafe's pharmaceutical dispensers, Dosell. The procurement includes 150-400 units, with an estimated value of SEK 5.5–13.8 million. The contract is owned by Dosell AB, a wholly-owned subsidiary of iZafe Group.

The contract period is two years with the possibility of an additional two-year extension, and the contract will be signed no earlier than 10 days after the award, the time required by procurement rules to elapse before a contract can be signed.
This is merely a decision of award and is not legally binding until a contract has been entered into.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe group has won procurement for pharmaceutical robots potentially worth SEK 5.5-13.8 million

100512242 Dosell Lkemedelsautomat

iZafe Group Board Member Bosse Johansson Purchases 800,000 Shares

iZafe Group's board member, Bosse Johansson, acquired 800,000 Class B shares in the company yesterday, valued at 216,000 SEK (0.27 SEK per share).

The purchase was made yesterday, on November 30th. Bosse Johansson's total shareholding in iZafe now amounts to these 800,000 Class B shares.

"Acquiring shares in iZafe is a step that demonstrates my confidence in the company's direction and potential. I look forward to continuing to contribute to our collective success and supporting the company's development," says Bosse Johansson.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group Board Member Bosse Johansson Purchases 800,000 Shares

Bosse Johansson

iZafe Group presented at Stora Aktiedagarna

iZafe Group's CEO, Anders Segerström, presented the company at the Aktiespararna’s event Stora Aktiedagarna on November 29. The presentation was held in Swedish and includes updates on the acquisition of Pilloxa, the significance of winning the procurement in Sweden, and the status of Dosell's existing markets.

You can watch the presentation here.
You can also find this presentation and previous ones here

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group presented at Stora Aktiedagarna

Stora Aktiedagen

iZafe Group presents at the “Stora Aktiedagarna”

iZafe Group (publ.) hereby announces that CEO Anders Segerström will present an investor presentation on Wednesday, November 29th at 4:25 PM at the "Stora Aktiedagarna" in Stockholm.

On Wednesday, November 29th at 4:25 PM, iZafe will present its operations at the "Stora Aktiedagarna" in Stockholm. The address is Birger Jarlsgatan 61 A. The presentation will also be broadcast live in Swedish at https://invitepeople.com/public/events/af87c9f59a/pages/aa3d4312cf and will be available afterwards on the Youtube channel of Aktiespararna as well as on iZafe's website.

Questions can be sent via SMS to the number +46(0) 79-347 98 45.
For more information: https://invitepeople.com/events/af87c9f59a

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

Anders_Segerstrom

iZafe Group presents at the "Stora Aktiedagarna"

iZafe Group and Atea Sweden have entered into an agreement with VGR in the field of welfare technology

iZafe Group AB ("iZafe Group") announces that the agreement with the Västra Götaland Region (VGR) for the delivery of Dosell medication dispensers has now been concluded. This follows the earlier communication of the award decision and covers 1,800 units, with a maximum of 2,250. The agreement is owned by Atea Sweden AB.

This new agreement, extending until 2025 with the possibility of an extension until 2027, underscores iZafe Group's commitment to enhancing the independence of home care recipients through advanced welfare technology.

The framework agreement includes medication robots from Dosell and has an estimated value of SEK 42–52 million. In addition to VGR, 46 municipalities are connected for call-offs under the agreement.

"By signing this agreement, we take another important step forward in providing efficient solutions for medication management. Our collaboration with Atea Sweden and the newly signed agreement with VGR marks a milestone for us in the healthcare and welfare technology sector," says Anders Segerström, CEO of iZafe Group.

Under the agreement, iZafe Group will supply Dosell medication dispensers to care recipients in VGR, aiming to enhance their independence and safety. "We are proud to contribute to improved healthcare quality and more efficient medication management through our innovative products," Segerström adds.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group and Atea Sweden have entered into an agreement with VGR in the field of welfare technology

Dosell VGR Nyhet

iZafe Group announces the appointment of nomination committee

iZafe Group AB (publ.) is pleased to announce that the company's major shareholders have appointed a nomination committee in consultation with the chairman of the board, Björn Rosengren. This step marks a significant milestone in enhancing corporate governance and ensuring that the company's leadership is aligned with shareholder interests and strategic objectives.

The Nomination Committee comprises the following members, representing a diverse mix of the company's ownership:

Patrik Björn, representing personal holdings through Gästrike Nord Invest AB
Stefan Wård, representing personal holdings
Marc Tarruell Tibau, representing personal holdings through Timedi S.L.
Björn Rosengren, Chairman of the Board, iZafe Group AB

Stefan Wård has been appointed as the Chairman of the Nomination Committee.

The Nomination Committee represents approximately 33% of the total number of outstanding shares and votes.

The primary responsibility of the Nomination Committee is to prepare and present proposals for the Annual General Meeting, on May 30 2024, regarding the election of the meeting's chairman, the Board of Directors, the Chairman of the Board, and auditors. The committee will also propose fees for board members and remuneration for auditors.

Shareholders in iZafe Group are encouraged to submit proposals to the Chairman of the Nomination Committee. Submissions can be made via email at or by postal mail to: iZafe Group, Attn: Nomination Committee, David Bagares Gata 3, 111 38 Stockholm, Sweden.

This initiative underscores iZafe Group's commitment to robust corporate governance practices that support the company's long-term strategy and value creation for shareholders.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group announces the appointment of nomination committee

Valberedning 2024

iZafe Group, in collaboration with Atea Sweden, has won a procurement potentially worth 42-52 MSEK.

iZafe Group AB ("iZafe Group") announces that, in partnership with Atea Sverige AB, they have been awarded a contract with Västra Götalandsregionen for the provision of iZafe's medication dispensers, Dosell. The contract covers 1,800 units, up to a maximum of 2,250 units, with an estimated value of 42–52 MSEK. The agreement is held by Atea Sverige AB.

The contract term is for two years, with the possibility of a further two-year extension, and the contract will be signed no earlier than after a period of 10 days, which is the time that must elapse after awarding, according to procurement regulations, before a contract can be signed.
This is merely a decision of award and is not legally binding until a contract has been entered into.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group, in collaboration with Atea Sweden, has won a procurement potentially worth 42-52 MSEK.

100512242-dosell-lkemedelsautomat

iZafe Group has successfully completed the implementation of Dosell in Spain and ships first 30 units

iZafe Group AB ("iZafe Group") is pleased to announce the successful implementation of their medication robot, Dosell, in Spain. The company has now completed all necessary technical integrations and adjustments required to launch Dosell in the Spanish market after a series of successful integrations. These adaptations encompassed both technical refinements to the Dosell unit itself and the platform, as well as extensive developments and adjustments by our collaboration partner.

As a significant step forward, iZafe Group has now delivered the first 30 Dosell units to Ti-Medi to commence practical testing of the customer journey over the nexts months. This phase of the pilot program will contribute to ensuring a seamless launch and customer experience. Upon successful completion of the testing phase, commercial sales will commence after the turn of the year, in accordance with the previously communicated plan.

"We are thrilled to announce the successful delivery of our cutting-edge pharmaceutical robot, Dosell, to the thriving market of Spain. This marks a significant milestone in our mission to helping patients taking the right medication at the right time in yet another country. We are committed to providing innovative solutions that empower healthcare professionals and improve patient care. This achievement is a testament to the hard work and dedication of our team, and we look forward to making a positive impact on the healthcare landscape in Spain and beyond." Says Anders Segerström, CEO of iZafe Group AB

"We're excited to announce a big change in our business model as we start focusing on serving individual consumers (B2C). This shift is a major milestone for us, and we know there's a lot of work to do. We're staying dedicated to working closely with our trusted pharmacy partners to make sure our pilot program gets the attention and resources it needs. We're confident that by leveraging our current partnerships and industry knowledge, this initiative will be a valuable learning experience. We're teaming up with iZafe to bring innovative solutions to the B2C market in the MDS industry." Rafa Tibau, CIO of Ti-Medi.

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution and the connected dose bag Pilloxa. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

iZafe Group has successfully completed the implementation of Dosell in Spain and ships first 30 units

Rafa Ti Medi